Surgery. 1988 Mar;103(3):278-88.
In an investigation of the indications for hepatic resection in the treatment of colorectal carcinoma metastases, the records of 859 patients who had undergone this procedure were reviewed. This patient group, from 24 institutions, was found to have a 5-year actuarial survival of 33% and a 5-year actuarial disease-free survival of 21%. The only factors that might by themselves be considered contraindications to hepatic resection are the presence of positive hepatic nodes, the presence of resectable extrahepatic metastases, or the presence of four or more metastases. Other factors that had a negative effect on long-term survival were margins of resection on the liver metastases less than or equal to 1 cm (S [5-year actuarial survival] = 23%), the presence of positive mesenteric nodes in the primary tumor specimen (S = 23%), and a disease-free interval of less than 1 year (S = 24%). The effect of any one of these factors was not great enough to contraindicate resection. However, combinations of prognostic factors must be considered before resection is recommended. The overall 5-year survival rate for this large series has been very satisfying. Decision making in the future must take into account such factors as number of metastases, extrahepatic involvement, and stage of the primary tumor.
在一项关于肝切除治疗结直肠癌肝转移适应证的调查中,回顾了859例行该手术患者的记录。这组来自24个机构的患者5年精算生存率为33%,5年无病精算生存率为21%。仅靠自身可能被视为肝切除禁忌证的因素为肝门淋巴结阳性、存在可切除的肝外转移或存在4个或更多转移灶。对长期生存有负面影响的其他因素包括肝转移灶切缘小于或等于1 cm(5年精算生存率=23%)、原发肿瘤标本中肠系膜淋巴结阳性(5年精算生存率=23%)以及无病间期小于1年(5年精算生存率=24%)。这些因素中任何一个的影响都不足以成为切除的禁忌证。然而,在建议切除之前必须考虑预后因素的组合。这个大样本系列的总体5年生存率一直非常令人满意。未来的决策必须考虑转移灶数量、肝外受累情况和原发肿瘤分期等因素。